-
HBKU develops model to predict FDA-approved drug response for lung cancer patients
23 Dec 2022 06:36 GMT
… for lung cancer patients.
To help in tackling drug resistance in lung cancers with … (PDRP) to predict responses to Gefitinib and Erlotinib, small molecule TKIs … that EFGR-mutated lung cancer is a major contributor to lung cancer mortality worldwide …
-
Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for a Certain Group of Tyrosine Kinase Inhibitors for Treatment of Non-Small Cell Lung Cancer Patients
21 Dec 2022 13:14 GMT
… patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal … (erlotinib), Tagrisso (osimertinib) and Iressa (gefitinib). Moving forward, FoundationOne Liquid CDx … ) mutations in non-small cell lung cancer.” https://www.sciencedirect …
-
LncRNA AFAP1-AS1 Induces Gefitinib Resistance of Lung Adenocarcinoma Through the miR-653-5p/AGR2 Axis
05 Jan 2023 06:41 GMT
… lung tumor cells via exosomes and confer them gefitinib … spread, including lung cancer. Importantly, increasing … gefitinib. Therefore, AGR2 contributes to lung cancer gefitinib resistance and thereby promotes lung cancer … -small cell lung cancers. Anticancer Res …
-
EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
02 Dec 2022 13:00 GMT
… metastatic non-small cell lung cancer (NSCLC) with activating … approximately 85% of all lung cancers, have EGFR mutations.2 … metastatic non-small cell lung cancer with EGFR mutations, … survival as compared to gefitinib. Secondary endpoints include overall …
-
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
11 Nov 2022 13:34 GMT
… lung cancer medicines and the next wave of innovations, including osimertinib and gefitinib … people with lung cancer, including and … .
References
Lungevity. Lung Cancer Statistics. Available at … #47;lung-cancer-awareness/lung-cancer-statistics#1 …
-
Imfinzi and Imjudo with chemotherapy approved in US for patients with metastatic non-small cell lung cancer
11 Nov 2022 07:15 GMT
… MD, Director of Lung Cancer Research, Sarah Cannon … Metastatic non-small cell lung cancer remains a significant treatment … Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi (durvalumab) and … improvements for people with lung cancer, including and beyond …
-
In Progressive Lung Cancer Second Biopsies May Be the Norm Now
05 Oct 2022 16:58 GMT
… not routinely done for lung cancers. But with the advent … with erlotinib or gefitinib (TRIBUTE, Tarceva Lung Cancer Investigation Trial, INTACT … for the Study of Lung Cancer and a current board … member of the Lung Cancer Research Foundation.
This article …
-
[ESMO 2022] Lung cancer treatment develops from strength to strength – except for Korea?
15 Sep 2022 07:18 GMT
… cancer expert by chairing many lung cancer sessions and making presentations … non-small cell lung cancer with the existing “Iresa (ingredient: gefitinib)” therapy, and … developed in Korea, many domestic lung cancer patients could get treatment opportunities …
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
11 Sep 2022 16:04 GMT
… lung cancer medicines and the next wave of innovations, including osimertinib and gefitinib … for people with lung cancer, including and beyond … Patients With HER2-Mutant Lung Cancers. Cancer. 2019; … HER2-mutant advanced lung cancer: chemotherapies versus HER2 …
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
11 Sep 2022 13:53 GMT
… lung cancer medicines and the next wave of innovations, including osimertinib and gefitinib … for people with lung cancer, including and beyond … Patients With HER2-Mutant Lung Cancers. Cancer. 2019; … HER2-mutant advanced lung cancer: chemotherapies versus HER2 …
About
© 1995-2023